Design and application of magnetic-based theranostic nanoparticle systems

Recent Patents on Biomedical Engineering

Volumn 6, Issue 1, 2013, Pages 47-57

  Wadajkar, Aniket S ^a,b   Menon, Jyothi U ^a,b   Kadapure, Tejaswi ^a,b   Tran, Richard T ^c   Yang, Jian ^c   Nguyen, Kytai T ^a,b  

^a The University of Texas at Arlington   (United States)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Hyperthermia; Imaging agents; Magnetic nanoparticles; Polymeric shell; Theranostics; Therapeutic agents

Indexed keywords

HYPERTHERMIA; IMAGING AGENT; MAGNETIC NANO-PARTICLES; POLYMERIC SHELL; THERANOSTICS; THERAPEUTIC AGENTS;

BIOCOMPATIBILITY; DIAGNOSIS; DISEASE CONTROL; DISEASES; FUNCTIONAL GROUPS; FUNCTIONAL POLYMERS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES;

NANOMAGNETICS;

EID: 84876921213     PISSN: 18747647     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874764711306010007     Document Type: Review

References (96)

1. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. AdvancedDrug Delivery Reviews. 2010; 62(11): 1064-79.
2. Bardhan R, Lal S, Joshi A, Halas NJ. Theranostic nanoshells: fromprobe design to imaging and treatment of cancer. Acc Chem Res.2011 Oct 18; 44(10): 936-46.
3. Babincova M, Babinec P. Magnetic drug delivery and targeting:principles and applications. Biomed Pap Med Fac Univ PalackyOlomouc Czech Repub. 2009 Dec; 153(4): 243-50.
4. Bonnemain B. Superparamagnetic agents in magnetic resonanceimaging: physicochemical characteristics and clinical applications. A review. Journal of drug targeting. 1998; 6(3): 167-74.
5. Mornet S, Vasseur S, Grasset F, Duguet E. Magnetic nanoparticledesign for medical diagnosis and therapy. Journal of MaterialsChemistry. 2004; 14(14): 2161-75.
6. Shubayev VI, Pisanic TR, 2nd, Jin S. Magnetic nanoparticles fortheragnostics. Advanced drug delivery reviews. 2009 Jun 21; 61(6):467-77.
7. Strijkers GJ, Kluza E, Van Tilborg GA, van der Schaft DW, GriffioenAW, Mulder WJ, et al. Paramagnetic and fluorescentliposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis. 2010 Jun; 13(2): 161-73.
8. Dobson J. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene therapy. 2006 Feb; 13(4): 283-7.
9. Gupta AK, Wells S. Surface-modified superparamagnetic nanoparticlesfor drug delivery: preparation, characterization, and cytotoxicitystudies. IEEE transactions on nanobioscience. 2004 Mar; 3(1):66-73.
10. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxidenanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011 Oct 18;44(10): 842-52.
11. Arami H, Stephen Z, Veiseh O, Zhang M. Chitosan-coated iron oxidenanoparticles for molecular imaging and drug delivery. Advances inPolymer Science: Springer Berlin / Heidelberg 2011: 163-84.
12. Rahimi M, Meletis EI, You S, Nguyen K. Formulation and characterizationof novel temperature sensitive polymer-coated magneticnanoparticles. J Nanosci Nanotechnol. 2010 Sep; 10(9): 6072-81.
13. Tataru G, Popa M, Desbrieres J. Magnetic microparticles based onnatural polymers. Int J Pharm. 2011 Feb 14; 404(1-2): 83-93.
14. Tassa C, Shaw SY, Weissleder R. Dextran-Coated Iron OxideNanoparticles: A Versatile Platform for Targeted Molecular Imaging, Molecular Diagnostics, and Therapy. Accounts of ChemicalResearch. 2011 06/102012/05/01; 44(10): 842-52.
15. Kaushik A, Khan R, Solanki PR, Pandey P, Alam J, Ahmad S, etal. Iron oxide nanoparticles-chitosan composite based glucose biosensor. Biosensors and Bioelectronics. 2008; 24(4): 676-83.
16. Kim EH, Ahn Y, Lee HS. Biomedical applications of superparamagneticiron oxide nanoparticles encapsulated within chitosan. Journal of Alloys and Compounds. 2007; 434âD 435(0): 633-6.
17. Chattopadhyay P, Gupta RB. Supercritical CO2 based productionof magnetically responsive micro-and nanoparticles for drug targeting. Ind Eng Chem Res. 2002 Oct 25; 41(24): 6049-58.
18. Sahoo SK, Dilnawaz F, Singh A, inventors; Water dispersibleglyceryl monooleate magnetic nanoparticle formulation. Internationalpatent WO2010/134087A1. 2010.
19. Nguyen KT, Rahimi M, Kona S, Lin A, inventors; Board of Regents, The University of Texas System, Austin, TX, assignee. Compositions and methods for thermo-sensitive nanoparticles andmagnetic nanoparticles. United Sates patent US2011/0097416A1.2011.
20. Yuan Q, Venkatasubramanian R, Hein S, Misra RDK. A stimulusresponsivemagnetic nanoparticle drug carrier: Magnetite encapsulatedby chitosan-grafted-copolymer. Acta Biomaterialia. 2008;4(4): 1024-37.
21. Fan L, Wu H, Zhang H, Li F, Yang T-h, Gu C-h, et al. Novel superpH-sensitive nanoparticles responsive to tumor extracellular pH. Carbohydrate Polymers. 2008; 73(3): 390-400.
22. Kamaly N, Miller AD. Paramagnetic liposome nanoparticles forcellular and tumour imaging. Int J Mol Sci. 2010; 11(4): 1759-76.
23. Namiki Y, Fuchigami T, Tada N, Kawamura R, Matsunuma S, Kitamoto Y, et al. Nanomedicine for cancer: lipid-based nanostructuresfor drug delivery and monitoring. Acc Chem Res. 2011 Oct18; 44(10): 1080-93.
24. Li X, Li H, Liu G, Deng Z, Wu S, Li P, et al. Magnetite-loadedfluorine-containing polymeric micelles for magnetic resonance imagingand drug delivery. Biomaterials. 2012; 33(10): 3013-24.
25. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications incancer. Annual review of biomedical engineering. 2007; 9: 257-88.
26. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment:Passive and active tumor targeting of nanocarriers for anticancerdrug delivery. J Control Release. 2010 Dec 1; 148(2): 135-46.
27. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascularpermeability and the EPR effect in macromolecular therapeutics: areview. Journal of Controlled Release. 2000; 65(1-2): 271-84.
28. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imagingand drug delivery. Adv Drug Deliv Rev. 2008 Aug 17; 60(11):1252-65.
29. Yu MK, Jeong YY, Park J, Park S, Kim JW, Min JJ, et al. Drug-Loaded Superparamagnetic Iron Oxide Nanoparticles for CombinedCancer Imaging and Therapy In Vivo. Angewandte ChemieInternational Edition. 2008; 47(29): 5362-5.
30. Satchi-Fainaro R, Hailu H, Davies JW, Summerford C, Duncan R. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a modelcombination. Bioconjugate chemistry. 2003 Jul-Aug; 14(4): 797-804.
31. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancertargeting and imaging with semiconductor quantum dots. Nat Biotech.2004; 22(8): 969-76.
32. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticlesfor drug delivery in cancer. Clin Cancer Res. 2008 Mar 1;14(5): 1310-6.
33. Marcucci F, Lefoulon F. Active targeting with particulate drugcarriers in tumor therapy: fundamentals and recent progress. DrugDiscovery Today. 2004; 9(5): 219-28.
34. Yao V, Berkman CE, Choi JK, O'Keefe DS, Bacich DJ. Expressionof prostate-specific membrane antigen (PSMA), increases cell folateuptake and proliferation and suggests a novel role for PSMA inthe uptake of the non-polyglutamated folate, folic acid. Prostate.2010 Feb 15; 70(3): 305-16.
35. Wang LF, Lin JJ, Chen JS, Huang SJ, Ka JH, Wang YM, et al., inventors; Kaohsiung Medical University, Kaohsiung City, TW, assignee. Folic acid-mediated magnetic nanoparticle clusters forcombined targeting, diagnosis, and therapy applications. UnitedStates patent US20110085987A1. 2011.
36. Kaaki K, Herve-Aubert K, Chiper M, Shkilnyy A, Souce M, BenoitR, et al. Magnetic nanocarriers of doxorubicin coated withpoly(ethylene glycol) and folic acid: relation between coating structure, surface properties, colloidal stability, and cancer cell targeting. Langmuir. 2011 Jan 17; 28(2): 1496-505.
37. Kievit FM, Stephen ZR, Veiseh O, Arami H, Wang T, Lai VP, etal. Targeting of Primary Breast Cancers and Metastases in a TransgenicMouse Model Using Rationally Designed MultifunctionalSPIONs. ACS Nano. 2012 02/102012/04/27; 6(3): 2591-601.
38. Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellarnanomedicine for cancer therapy. Experimental biology andmedicine (Maywood, NJ. 2009 Feb; 234(2): 123-31.
39. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer research. 2000 Dec 1; 60(23): 6641-8.
40. Chertok B, Moffat BA, David AE, Yu F, Bergemann C, Ross BD, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRImonitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4): 487-96.
41. Wang YX. Superparamagnetic iron oxide based MRI contrastagents: current status of clinical application. Quant Imaging MedSurg. 2011; 1(1): 35-40.
42. Bae KH, Lee K, Kim C, Park TG. Surface functionalized hollowmanganese oxide nanoparticles for cancer targeted siRNA deliveryand magnetic resonance imaging. Biomaterials. 2011 Jan; 32(1):176-84.
43. Ahren M, Selegard L, Klasson A, Soderlind F, Abrikossova N, Skoglund C, et al. Synthesis and characterization of PEGylatedGd2O3 nanoparticles for MRI contrast enhancement. Langmuir.2010 Apr 20; 26(8): 5753-62.
44. Geraldes CF, Laurent S. Classification and basic properties ofcontrast agents for magnetic resonance imaging. Contrast media &molecular imaging. 2009 Jan-Feb; 4(1): 1-23.
45. Vymazal J, Spuentrup E, Cardenas-Molina G, Wiethoff AJ, HartmannMG, Caravan P, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinicalstudy of feasibility. Invest Radiol. 2009 Nov; 44(11): 697-704.
46. Winter PM, Caruthers SD, Yu X, Song SK, Chen J, Miller B, et al. Improved molecular imaging contrast agent for detection of humanthrombus. Magn Reson Med. 2003 Aug; 50(2): 411-6.
47. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L. Magneto/optical annexin V, a multimodal protein. Bioconjug Chem.2004 Sep-Oct; 15(5): 1062-7.
48. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dotbioconjugates for imaging, labelling and sensing. Nature materials.2005 Jun; 4(6): 435-46.
49. Erathodiyil N, Ying JY. Functionalization of inorganic nanoparticlesfor bioimaging applications. Accounts of chemical research.2011 Oct 18; 44(10): 925-35.
50. Fan HM, Olivo M, Shuter B, Yi JB, Bhuvaneswari R, Tan HR, etal. Quantum dot capped magnetite nanorings as high performancenanoprobe for multiphoton fluorescence and magnetic resonanceimaging. Journal of the American Chemical Society. 2010 Oct 27;132(42): 14803-11.
51. Koole R, van Schooneveld MM, Hilhorst J, Castermans K, CormodeDP, Strijkers GJ, et al. Paramagnetic lipid-coated silicananoparticles with a fluorescent quantum dot core: a new contrastagent platform for multimodality imaging. Bioconjugate chemistry.2008 Dec; 19(12): 2471-9.
52. Zhang M, Gunn JW, Yee C, inventors; Fred Hutchinson CancerResearch Center and University of Washington, Seattle, WA, assignee. Magnetic nanoparticle and method for imaging T cells patentUS2011/0250146A1. 2011.
53. Jiang J, Gu H, Shao H, Devlin E, Papaefthymiou GC, Ying JY. Bifunctional Fe3O4-Ag heterodimer nanoparticles for two-photonfluorescence imaging and magnetic manipulation. Adv Mater.2008; 20: 4403-7.
54. Shi W, Sahoo Y, Zeng H, Ding Y, Swihart MT, Prasad PN. Anisotropicgrowth of PbSe nanocrystals on Au-Fe3O4 hybrid nanoparticles. Adv Mater. 2006; 18: 1889-94.
55. Devaraj NK, Keliher EJ, Thurber GM, Nahrendorf M, WeisslederR. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjugatechemistry. 2009 Feb; 20(2): 397-401.
56. Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dye-loaded, multifunctionaliron oxide nanoparticles for combined targeted cancertherapy and dual optical/magnetic resonance imaging. Small. 2009Aug 17; 5(16): 1862-8.
57. Martin AL, Hickey JL, Ablack AL, Lewis JD, Luyt LG, Gillies ER. Synthesis of bombesin-functionalized iron oxide nanoparticles andtheir specific uptake in prostate cancer cells. J Nanopart Res. 2010;12(5): 1599-608.
58. Lee CM, Jeong HJ, Cheong SJ, Kim EM, Kim DW, Lim ST, et al. Prostate cancer-targeted imaging using magnetofluorescent polymericnanoparticles functionalized with bombesin. Pharm Res. 2010Apr; 27(4): 712-21.
59. Schmieder AH, Caruthers SD, Zhang H, Williams TA, RobertsonJD, Wickline SA, et al. Three-dimensional MR mapping of angiogenesiswith alpha5beta1(alpha nu beta3)-targeted theranosticnanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 2008 Dec; 22(12): 4179-89.
60. Veiseh O, Sun C, Fang C, Bhattarai N, Gunn J, Kievit F, et al. Specific targeting of brain tumors with an optical/magnetic resonanceimaging nanoprobe across the blood-brain barrier. CancerRes. 2009 Aug 1; 69(15): 6200-7.
61. Yang J, Zhang Y, Gautam S, Liu L, Dey J, Chen W, et al. Developmentof aliphatic biodegradable photoluminescent polymers. Proc Natl Acad Sci U S A. 2009 Jun 23; 106(25): 10086-91.
62. Yang J, Gautam S, inventors; Board of Regents, The University ofTexas System, Austin, TX, assignee. Biodegradable photoluminescentpolymers. United States patent US2011/0183435A1. 2011.
63. Liu L, Zhang J, Su X, Mason RP. In vitro and in vivo assessment ofCdTe and CdHgTe toxicity and clearance. Journal of biomedicalnanotechnology. 2008 Dec 1; 4(4): 524-8.
64. Dutz S, Kettering M, Hilger I, Muller R, Zeisberger M. Magneticmulticore nanoparticles for hyperthermia--influence of particleimmobilization in tumour tissue on magnetic properties. Nanotechnology.2011 Jul 1; 22(26): 265102.
65. Erten A, Wrasidlo W, Scadeng M, Esener S, Hoffman RM, BouvetM, et al. Magnetic resonance and fluorescence imaging of doxorubicin-loaded nanoparticles using a novel in vivo model. Nanomedicine.2010 Dec; 6(6): 797-807.
66. Labhasetwar V, Leslie-Pelecky D, Jain T, inventors; University ofNebraska Medical Center, Omaha, NE, assignee. Multifunctionalmagnetic nanoparticles for imaging and drug delivery. UnitedStates patent US2007/0264199. 2007.
67. Yang J, Park SB, Yoon H-G, Huh YM, Haam S. Preparation ofpoly ε-caprolactone nanoparticles containing magnetite for magneticdrug carrier. International Journal of Pharmaceutics. 2006;324(2): 185-90.
68. McBain SC, Yiu HH, Dobson J. Magnetic nanoparticles for geneand drug delivery. Int J Nanomedicine. 2008; 3(2): 169-80.
69. Tietze R, Schreiber E, Lyer S, Alexiou C. Mitoxantrone loadedsuperparamagnetic nanoparticles for drug targeting: a versatile andsensitive method for quantification of drug enrichment in rabbit tissuesusing HPLC-UV. J Biomed Biotechnol. 2010; 2010: 1-8.
70. Nowicka AM, Kowalczyk A, Donten M, Krysinski P, Stojek Z. Influence of a magnetic nanoparticle as a drug carrier on the activityof anticancer drugs: Interactions of double stranded DNA anddoxorubicin modified with a carrier. Analytical Chemistry. 20092012/02/03; 81(17): 7474-83.
71. Xiang SD, Selomulya C, Ho J, Apostolopoulos V, Plebanski M. Delivery of DNA vaccines: an overview on the use of biodegradablepolymeric and magnetic nanoparticles. Wiley Interdisciplinary Reviews:Nanomedicine and Nanobiotechnology. 2010; 2(3): 205-18.
72. Mykhaylyk O, Sobisch T, Almstätter I, Sanchez-Antequera Y, Brandt S, Anton M, et al. Silica-iron oxide magnetic nanoparticlesmodified for gene delivery: A search for optimum and quantitativecriteria. Pharm Res. 2012: 1-22.
73. Lee JH, Lee K, Moon SH, Lee Y, Park TG, Cheon J. All-in-onetarget-cell-specific magnetic nanoparticles for simultaneous molecularimaging and siRNA delivery. Angew Chem Int Ed Engl.2009; 48(23): 4174-9.
74. Chertok B, David AE, Yang VC. Magnetically-enabled and MRmonitoredselective brain tumor protein delivery in rats via magneticnanocarriers. Biomaterials. 2011 Sept; 32(26): 6245-53.
75. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application offunctionalized magnetic nanoparticles. Journal of bioscience andbioengineering. 2005 Jul; 100(1): 1-11.
76. Reddy AM, Kwak BK, Shim HJ, Ahn C, Lee HS, Suh YJ, et al. Invivo tracking of mesenchymal stem cells labeled with a novel chitosan-coated superparamagnetic iron oxide nanoparticles using3.0T MRI. Journal of Korean medical science. 2010 Feb; 25(2): 211-9.
77. Branca RT, Cleveland ZI, Fubara B, Kumar CS, Maronpot RR, Leuschner C, et al. Molecular MRI for sensitive and specific detectionof lung metastases. Proceedings of the National Academy ofSciences of the United States of America. 2010 Feb 23; 107(8):3693-7.
78. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, TabatabaeiS, van de Kaa CH, et al. Noninvasive Detection of Clinically OccultLymph-Node Metastases in Prostate Cancer. New EnglandJournal of Medicine. 2003; 348(25): 2491-9.
79. Lubbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, et al. Clinical experiences with magnetic drug targeting:a phase I study with 4'-epidoxorubicin in 14 patients with advancedsolid tumors. Cancer research. 1996 Oct 15; 56(20): 4686-93.
80. Bertorelle F, Wilhelm C, Roger J, Gazeau F, Menager C, Cabuil V. Fluorescence-modified superparamagnetic nanoparticles: intracellularuptake and use in cellular imaging. Langmuir. 2006 Jun 6;22(12): 5385-91.
81. Li ZF, Ruckenstein E. Water-soluble poly(acrylic acid) graftedluminescent silicon nanoparticles and their use as fluorescent biologicalstaining labels. Nano Letters. 2004 June 18; 4(8): 1463-7.
82. Sun C, Fang C, Stephen Z, Veiseh O, Hansen S, Lee D, et al. Tumor-targeted drug delivery and MRI contrast enhancement bychlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine(London, England). 2008 Aug; 3(4): 495-505.
83. Berry CC, Curtis ASG. Functionalisation of magnetic nanoparticlesfor applications in biomedicine. J Phys D: Appl Phys. 2003;36(13).
84. Chen Y, Chen BA. Application and advancement of magnetic ironoxidenanoparticles in tumor-targeted therapy. Chinese journal ofcancer. 2010 Jan; 29(1): 125-8.
85. Le Renard PE, Jordan O, Faes A, Petri-Fink A, Hofmann H, Rufenacht D, et al. The in vivo performance of magnetic particleloadedinjectable, in situ gelling, carriers for the delivery of localhyperthermia. Biomaterials. 2010 Feb; 31(4): 691-705.
86. Tseng HY, Lee GB, Lee CY, Shih YH, Lin XZ. Localised heating oftumours utilising injectable magnetic nanoparticles for hyperthermiacancer therapy. IET Nanobiotechnol. 2009 Jun; 3(2): 46-54.
87. Wang ZY, Song J, Zhang DS. Nanosized As2O3/Fe2O3 complexescombined with magnetic fluid hyperthermia selectively target livercancer cells. World J Gastroenterol. 2009 Jun 28; 15(24): 2995-3002.
88. Safarík I, Safaríková M. Use of magnetic techniques for the isolationof cells. J Chromatogr B Biomed Sci Appl. 1999 Feb 5; 722(1-2): 33-53.
89. Owen CS. Magnetic cell sorting using collodial protein-magnetite. J Immunogenet. 1989 Apr; 16(2): 117-23.
90. Rye PD. Sweet and sticky: carbohydrate-coated magnetic beads. Bio/Technology. 1996; 14: 155-7.
91. Xu H, Aguilar ZP, Yang L, Kuang M, Duan H, Xiong Y, et al. Antibody conjugated magnetic iron oxide nanoparticles for cancercell separation in fresh whole blood. Biomaterials. 2011 Dec;32(36): 9758-65.
92. Gupta AK, Gupta M. Cytotoxicity suppression and cellular uptakeenhancement of surface modified magnetic nanoparticles. Biomaterials.2005 May; 26(13): 1565-73.
93. Leem G, Sarangi S, Zhang S, Rusakova I, Brazdeikis A, LitvinovD, et al. Surfactant-controlled size and shape evolution of magneticnanoparticles. Cryst Growth Des. 2008 Dec 2; 9(1): 32-4.
94. Rabias I, Tsitrouli D, Karakosta E, Kehagias T, Diamantopoulos G, Fardis M, et al. Rapid magnetic heating treatment by highlycharged maghemite nanoparticles on Wistar rats exocranial gliomatumors at microliter volume. Biomicrofluidics. 2010 June 21; 4(2).
95. He X, Wang K, Tan W, Liu B, Lin X, Huang S, et al. A novel genecarrier based on amino-modified silica nanoparticles. Chinese ScienceBulletin. 2003; 48(3): 223-8.
96. Villanueva A, Nete MC, Roca AG, Calero M, Veintemillas-Verdaguer S, Serna CJ, et al. The influence of surface functionalizationon the enhanced internalization of magnetic nanoparticles incancer cells. Nanotechnology. 2009 20(11): 115103.